SCHEMBL496083

SCHEMBL496083

CC(=O)N(C)C[C@@H](O)[C@@H](Cc1cc(F)ccc1F)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.41
SCN9A Q15858 2/20 0.40
DPP4 P27487 4/20 0.40
DPP9 Q86TI2 3/20 0.40
DPP8 Q6V1X1 2/20 0.40
DPP7 Q9UHL4 2/20 0.40
KLK5 Q9Y337 2/20 0.40
CTSS P25774 3/20 0.38
CTSK P43235 3/20 0.38
PSEN1 P49768 2/20 0.38
PSEN2 P49810 2/20 0.38
APH1B Q8WW43 2/20 0.38
NCSTN Q92542 2/20 0.38
APH1A Q96BI3 2/20 0.38
PSENEN Q9NZ42 2/20 0.38
GPR119 Q8TDV5 1/20 0.36
PTPN1 P18031 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL496081 1.00 RIPK1 (0.41) RIPK1SCN9ADPP4DPP9DPP8
SCHEMBL495865 0.84 KLK5 (0.43) RIPK1SCN9ADPP4DPP9DPP8
SCHEMBL495863 0.84 KLK5 (0.43) RIPK1SCN9ADPP4DPP9DPP8
SCHEMBL496196 0.83 SCN9A (0.42) RIPK1SCN9ADPP4DPP9DPP8
SCHEMBL496197 0.83 SCN9A (0.42) RIPK1SCN9ADPP4DPP9DPP8
SCHEMBL15062890 0.82 SCN9A (0.40) RIPK1SCN9ADPP4DPP9DPP8
SCHEMBL496052 0.78 KLK5 (0.59) KLK5CTSSCTSKPSEN1PSEN2
SCHEMBL496051 0.78 KLK5 (0.59) KLK5CTSSCTSKPSEN1PSEN2
SCHEMBL496228 0.78 DPP4 (0.53) RIPK1DPP4DPP9DPP8DPP7
SCHEMBL4693374 0.78 DPP4 (0.53) RIPK1DPP4DPP9DPP8DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910317-B1 1-AMINO LINKED COMPOUNDS LILLY CO ELI (US) 2013-07-03 EP disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207735-A1 1-Amino Linked Compounds DPP4, DPP3, DPP9 RIPK1 4046/4885SCN9A 467/4885DPP4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.